(Q45753077)

15 December 2017

title

Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts (English)

1 reference

15 December 2017

1 reference

1 reference

1 reference

1 reference

1 reference

1 reference

Davidkin I

1

1 reference

15 December 2017

Valle M

series ordinal

2

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 December 1998

1 reference

15 December 2017

published in

Vaccine

1 reference

15 December 2017

volume

16

1 reference

15 December 2017

issue

20

1 reference

15 December 2017

page(s)

2052-2057

1 reference

15 December 2017

Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Increase of vaccination coverage by mass media and individual approach: intensified measles, mumps, and rubella prevention program in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Secondary immune responses in parents of children with recent measles

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Live measles vaccine: a 21 year follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Measles vaccine: a 27-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Long-term antibody response after measles vaccination in an isolated arctic society in Greenland

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Further-attenuated measles vaccine: characteristics and use.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Methods for screening the naturally acquired and vaccine-induced immunity to the measles virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

The plaque-neutralization test as a measure of prior exposure to measles virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Enzyme-linked immunosorbent assay for evaluation of immunity to measles virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Persistence of measles antibody in the absence of circulating natural virus five years after immunization of an isolated virgin population with Edmonston B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Cellular Immunity in Measles Vaccine Failure: Demonstration of Measles Antigen-Specific Lymphoproliferative Responses despite Limited Serum Antibody Production after Revaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Persistence of Measles Antibody after Revaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Boosting effect of a second dose of measles vaccine given to 12-year-old children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Role of virus strain dm conventional and enhanced measles plaque neutralization test

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

Measles antibody: reevaluation of protective titers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

No measles in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900081-4

7 January 2021

10.1016/S0264-410X(98)00081-4

Identifiers

DOI

1 reference

15 December 2017

PubMed ID

9796064

1 reference

15 December 2017